Kids.O
Orthopediatrics Corp (KIDS.O) operates in the Medical Equipment & Supplies industry, generating revenue through the sale of medical devices, though specific product lines are not detailed in the available data.
Business. Orthopediatrics Corp (KIDS.O) operates in the Medical Equipment & Supplies industry, generating revenue through the sale of medical devices, though specific product lines are not detailed in the available data.
Analyst recommendations
9 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Orthopediatrics Corp (KIDS.O) operates in the Medical Equipment & Supplies industry, generating revenue through the sale of medical devices, though specific product lines are not detailed in the available data.
Orthopediatrics Corp maintains a capital structure characterized by moderate leverage and negative net cash. The company holds $19.6 million in cash and equivalents against $99.8 million in long-term debt, resulting in a debt-to-equity ratio of 0.29. This leverage profile is supported by a total equity base of $346.6 million and total assets of $508.6 million. The current ratio is not explicitly provided, but the negative net cash position flags a medium liquidity risk, indicating that the company relies on external financing or future cash flow generation to meet obligations.
Profitability metrics indicate significant operational challenges, with the company reporting a net loss of $39.6 million on revenues of $236.3 million. The gross profit of $172.7 million suggests a gross margin of approximately 73%, which is typical for specialized medical device manufacturers, but operating expenses exceed gross profit, leading to an operating loss of $39.2 million. Return on equity stands at -11.45% and return on assets at -7.8%, reflecting the inability to generate positive returns on invested capital in the current period. The negative EV/EBITDA of -15.98 further underscores the lack of earnings before interest, taxes, depreciation, and amortization.
Revenue concentration by segment or geography is not disclosed in the available data. The company’s total revenue of $236.3 million represents its entire top-line performance for the latest normalized period. Without segment breakdowns, it is not possible to assess the diversification of revenue streams or geographic exposure risks.
Growth trajectory analysis is limited due to the absence of historical period data. The current revenue figure of $236.3 million serves as the baseline for performance evaluation. Without year-over-year or quarter-over-quarter comparisons, the direction and magnitude of revenue growth cannot be determined from the provided inputs.
Risk assessment highlights medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, which may constrain financial flexibility. The low dilution risk suggests that the company is not currently engaging in significant equity issuance, supported by the identical basic and diluted share counts of 25.1 million.
Recent events include analyst coverage updates with a mean price target of $25.00 and a median target of $24.00, indicating a potential upside from the current market price of $20.11. The mean recommendation of 1.89 suggests a bullish sentiment among analysts, with 2 strong buys and 6 buys recorded. No specific news events or filing observations were provided beyond the reconciler enqueue notifications.
- Orthopediatrics Corp reports a net loss of $39.6 million on $236.3 million in revenue, indicating significant operational inefficiencies.
- The company carries $99.8 million in long-term debt against $19.6 million in cash, resulting in a negative net cash position and medium liquidity risk.
- Analyst sentiment is positive, with a mean price target of $25.00 and a mean recommendation of 1.89, suggesting expected future improvements.
- Return on equity is -11.45% and return on assets is -7.8%, reflecting poor capital efficiency in the current period.
- Dilution risk is low, with no difference between basic and diluted share counts, indicating stable equity structure.
Bull / Bear case
analysis pipelineIn focus — financials by report
Revenue $59.4M, +13,3% YoY; Operating income +24,1% YoY.
- ▍Revenue $59.4M, +13,3% YoY
- ▍Operating income +24,1% YoY
- ▍Net income −0,3% YoY
- ▍Free cash flow +31,6% YoY
- ▍Net margin -18.0%
Revenue $61.6M, +17,0% YoY; Operating income +41,9% YoY.
- ▍Revenue $61.6M, +17,0% YoY
- ▍Operating income +41,9% YoY
- ▍Net income +37,1% YoY
- ▍Free cash flow −140,7% YoY
- ▍Net margin -16.4%
Revenue $61.2M, +12,2% YoY; Operating income −7,2% YoY.
- ▍Revenue $61.2M, +12,2% YoY
- ▍Operating income −7,2% YoY
- ▍Net income −48,7% YoY
- ▍Free cash flow +67,9% YoY
- ▍Net margin -19.2%
Revenue $61.1M, +15,7% YoY; Operating income −88,1% YoY.
- ▍Revenue $61.1M, +15,7% YoY
- ▍Operating income −88,1% YoY
- ▍Net income −18,0% YoY
- ▍Free cash flow +32,1% YoY
- ▍Net margin -11.6%
Revenue $52.4M; Operating income -$11.0M.
- ▍Revenue $52.4M
- ▍Operating income -$11.0M
- ▍Net margin -20.3%
Revenue $52.7M; Operating income -$14.1M.
- ▍Revenue $52.7M
- ▍Operating income -$14.1M
- ▍Net margin -30.5%
Revenue $54.6M; Operating income -$8.8M.
- ▍Revenue $54.6M
- ▍Operating income -$8.8M
- ▍Net margin -14.5%
Revenue $52.8M; Operating income -$5.7M.
- ▍Revenue $52.8M
- ▍Operating income -$5.7M
- ▍Net margin -11.4%
Revenue $236.3M, +15,4% YoY; Operating income −2,6% YoY.
- ▍Revenue $236.3M, +15,4% YoY
- ▍Operating income −2,6% YoY
- ▍Net income −4,8% YoY
- ▍Free cash flow +11,9% YoY
- ▍Net margin -16.8%
Revenue $204.7M, +37,6% YoY; Operating income −43,0% YoY.
- ▍Revenue $204.7M, +37,6% YoY
- ▍Operating income −43,0% YoY
- ▍Net income −80,3% YoY
- ▍Free cash flow −49,1% YoY
- ▍Net margin -18.5%
Revenue $148.7M, +21,6% YoY; Operating income −5,3% YoY.
- ▍Revenue $148.7M, +21,6% YoY
- ▍Operating income −5,3% YoY
- ▍Net income −1 767,2% YoY
- ▍Free cash flow −621,8% YoY
- ▍Net margin -14.1%
Revenue $122.3M, +24,7% YoY; Operating income −40,9% YoY.
- ▍Revenue $122.3M, +24,7% YoY
- ▍Operating income −40,9% YoY
- ▍Net income +107,7% YoY
- ▍Free cash flow +120,0% YoY
- ▍Net margin 1.0%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,18 |
| Revenue | —no estimate | —no estimate | 265,2M USD |
| Operating income | —no estimate | —no estimate | -18,3M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- OrthoPediatrics Corp Market data — financials · 2026-07-31
- reconciler_enqueue (reconciler) on KIDS.O · 2026-07-31
- OrthoPediatrics Corp Market data — analyst estimates · 2026-07-31
- OrthoPediatrics Corp Market data — ESG · 2026-07-31
- KIDS.O HA canonical relationships · 2026-07-31
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$14M
- Investment Managers · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$18M
- Investment Managers · as of 2024-06-300,00 %$37M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2025-12-310,00 %$17M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$7M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- David R. BaileyPresident, Chief Executive Officer, Director
Insider activity
- Director · Common StockOther 11 436 · 2026-06-09
- Director · Common StockOther 11 436 · 2026-06-09
- Director · Common StockOther 11 436 · 2026-06-09
- Director · Common StockOther 11 436 · 2026-06-09
- Director · Common StockOther 11 436 · 2026-06-09
- Director, President and CEO · Common StockOther 119 140 · 2026-06-09
- Director · Common StockOther 11 436 · 2026-06-09
- Director · Common StockOther 11 436 · 2026-06-09
- Director · Common StockOther 11 436 · 2026-06-09
- Director · Common StockOther 11 436 · 2026-06-09
- General Counsel and Secretary · Common StockOther 2 479 · 2026-05-13
- Director, COO and CFO · Common StockSold 12 993 @ $17,25$224K · 2026-03-16
- General Counsel and Secretary · Common StockSold 8 614 @ $17,25$149K · 2026-03-16
- Pres. Trauma & Def. Correction · Common StockSold 8 596 @ $17,25$148K · 2026-03-16
- President of Scoliosis · Common StockSold 8 433 @ $17,25$145K · 2026-03-16
- Director, President and CEO · Common StockSold 19 535 @ $17,25$337K · 2026-03-16
- Director, COO and CFO · Common StockOther 77 405 · 2026-03-15
- Pres. Trauma & Def. Correction · Common StockOther 65 700 · 2026-03-15
- President of Scoliosis · Common StockOther 47 380 · 2026-03-15
- General Counsel and Secretary · Common StockOther 47 380 · 2026-03-15
- Director, President and CEO · Common StockOther 1 600 · 2025-12-29
- Director · Common StockOther 4 345 · 2025-11-10
- Director, COO and CFO · Common StockBought 5 076 @ $19,41$99K · 2025-08-21
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current assets (annual): USD 256.42MUnknown
- EPS (basic) (annual): USD-PER-SHARES -2Unknown
- Shares outstanding (annual): 25.09MUnknown
- Cost of revenue (annual): USD 63.69MUnknown
- Revenue (annual): USD 236.35MUnknown
- Total liabilities (annual): USD 162.03MUnknown
- Operating cash flow (annual): USD -4.85MUnknown
- Operating income (annual): USD -39.24MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -2Unknown
- Net income (annual): USD -39.65MUnknown
- Gross profit (annual): USD 172.66MUnknown
- Current liabilities (annual): USD 46.2MUnknown
- Shareholders' equity (annual): USD 346.6MUnknown
- Cash & equivalents (annual): USD 19.56MUnknown
- Long-term debt (annual): USD 106.01MUnknown
- R&D expense (annual): USD 9.1MUnknown
- Total operating expenses (annual): USD 211.9MUnknown
- Pre-tax income (annual): USD -39.19MUnknown
- Capex (annual): USD 11.11MUnknown
- Total assets (annual): USD 508.63MUnknown
- Total liabilities (annual): USD 118.64MUnknown
- Long-term debt (annual): USD 77.48MUnknown
- Gross profit (annual): USD 148.6MUnknown
- Revenue (annual): USD 204.73MUnknown